74 related articles for article (PubMed ID: 38388789)
1. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Deek MP; Sutera P; Jing Y; Gao R; Rothman E; Day H; Chang D; Dirix P; Armstrong AJ; Campbell B; Campos FL; Berenguer M; Ramotar M; Conde-Moreno A; Berlin A; Bosetti DG; Corcoran N; Koontz B; Mercier C; Siva S; Pryor D; Ost P; Huynh MA; Kroeze S; Stish B; Kiess A; Trock B; Tran PT; Gillessen S; Sweeney C
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38570239
[TBL] [Abstract][Full Text] [Related]
2. Optimal systemic therapy in men with low-volume prostate cancer.
Saxena A; Andrews J; Bryce AH; Riaz IB
Curr Opin Urol; 2024 May; 34(3):183-197. PubMed ID: 38445371
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-directed therapy in oligometastatic prostate cancer.
Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
[TBL] [Abstract][Full Text] [Related]
4. [Metastasis-directed therapy in prostate cancer].
Borkowetz A; Hölscher T
Urologie; 2024 Mar; 63(3):225-233. PubMed ID: 38388789
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
9. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
10. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ; de Almeida Luz M; De Giorgi U; Gleave M; Gotto GT; Pieczonka CM; Haas GP; Kim CS; Ramirez-Backhaus M; Rannikko A; Tarazi J; Sridharan S; Sugg J; Tang Y; Tutrone RF; Venugopal B; Villers A; Woo HH; Zohren F; Shore ND
N Engl J Med; 2023 Oct; 389(16):1453-1465. PubMed ID: 37851874
[TBL] [Abstract][Full Text] [Related]
11. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
[TBL] [Abstract][Full Text] [Related]
12. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
Tang C; Sherry AD; Haymaker C; Bathala T; Liu S; Fellman B; Cohen L; Aparicio A; Zurita AJ; Reuben A; Marmonti E; Chun SG; Reddy JP; Ghia A; McGuire S; Efstathiou E; Wang J; Wang J; Pilie P; Kovitz C; Du W; Simiele SJ; Kumar R; Borghero Y; Shi Z; Chapin B; Gomez D; Wistuba I; Corn PG
JAMA Oncol; 2023 Jun; 9(6):825-834. PubMed ID: 37022702
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus.
Zilli T; Achard V; Dal Pra A; Schmidt-Hegemann N; Jereczek-Fossa BA; Lancia A; Ingrosso G; Alongi F; Aluwini S; Arcangeli S; Blanchard P; Conde Moreno A; Couñago F; Créhange G; Dirix P; Gomez Iturriaga A; Guckenberger M; Pasquier D; Sargos P; Scorsetti M; Supiot S; Tree AC; Zapatero A; Le Guevelou J; Ost P; Belka C
Radiother Oncol; 2022 Nov; 176():199-207. PubMed ID: 36228761
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]